January 5, 2018 / 11:06 AM / 9 months ago

BRIEF-Biocryst Advancing Potential Treatment For Rare And Severely Debilitating Fibrodysplasia Ossificans Progressiva

Jan 5 (Reuters) - Biocryst Pharmaceuticals Inc:

* BIOCRYST ADVANCING POTENTIAL TREATMENT FOR RARE AND SEVERELY DEBILITATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

* BIOCRYST PHARMACEUTICALS - IND FOR NONCLINICAL DEVELOPMENT OF BCX9250,BCX9499 INITIATED WITH GOAL OF PROGRESSING TO PHASE 1 CLINICAL TRIALS IN H1 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below